Go ahead,

test us.

FACT 1

Not all early risk assessment “solutions” are the same, even though their claims may seem similar.

FACT 2

KidneyIntelXTM has received the first Breakthrough Device Designation from the FDA (publicly announced by any company) for an AI-enabled prognostic for kidney disease.

FACT 3

Renalytix is voluntarily pursuing a rigorous FDA review and marketing authorization process for KidneyIntelX.

For more information about our scientific standards and rigor, click Labs & Quality.

FACT 4

Only Renalytix founded this new bioprognosticTM methodology for kidney health via KidneyIntelX, which uniquely leverages biological factors demonstrated to better predict rapid disease progression.

Learn more

FACT 5

Only KidneyIntelX works in stages 1-3b, when it matters most.

Learn more

FACT 6

KidneyIntelX has a growing body of evidence via validation, utility and economic studies, including a demonstrated 72% improvement in predicting those patients who are at high risk for progression vs the current standard of care.

Learn more

FACT 7

Only KidneyIntelX has been clinically-validated to provide reproducible results and show clinical utility.

Learn more

FACT 8

KidneyIntelX has obtained a national payment rate from Medicare.

Learn more
Compare us